MYC and neuroblastoma: Here, these evidences confirmed that the molecular strategies aimed to downregulate MYCN in order to treat NB should be accomplished by a sustained activation of all the events, excluding those inducing side effects (such as c-MYC up-modulation), involved in the induction of ligands for NK cell-activating receptors.